Bristol warns against Reyataz/Viread combination
Executive Summary
Bristol-Myers Squibb sends "Dear Health Care Provider" letter Aug. 8 warning against use of Reyataz (atazanavir) in conjunction with Viread (tenofovir) for treatment of HIV. "The coadministration of unboosted Reyataz with tenofovir DF may lead to loss or lack of virologic response and possible resistance to Reyataz," the letter states. GlaxoSmithKline recently sent a "Dear Doctor" letter warning against using Ziagen and Epivir in combination with Viread (1"The Pink Sheet" Aug. 4, 2003, In Brief)...